

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Saturday, May 30, 2026

A randomized, active-controlled phase 3 study of ivonescimab + FOLFOX versus bevacizumab + FOLFOX as first-line treatment of metastatic colorectal cancer (mCRC): HARMONi-GI3.

Aparna Parikh, MD,
FASCO

Poster Session
Gastrointestinal Cancer: Colorectal and Anal
9:00am-12:00pm CT

Long-term survival results of perioperative chemoimmunotherapy with DCF and avelumab in locally advanced gastro-esophageal adenocarcinoma.

Thierry Alcindor, MD,
MSc

Poster Session
Gastrointestinal Cancer: Gastroesophageal, Pancreatic, and Hepatobiliary
9:00am-2:00pm CT

Interrupting sedentary time to improve cardiometabolic health and toxicity in patients with lymphoma receiving chemotherapy: The iSTAND trial.

Thierry Alcindor, MD,
MSc

Poster Session
Symptom Science and Palliative Care
1:30pm-4:30pm CT

An automated, EHR-integrated intervention system for patient-reported insomnia symptoms.

Eric Zhou, PhD

Poster Session
Symptom Science and Palliative Care
1:30pm-4:30pm CT

A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Glenn Hanna, MD

Poster Session
Head and Neck Cancer
1:30pm-4:30pm CT

OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.

Robert Haddad, MD,
FASCO

Poster Session
Head and Neck Cancer
1:30pm-4:30pm CT

Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.

Robert Haddad, MD,
FASCO

Poster Session
Head and Neck Cancer
1:30pm-4:30pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Sunday, May 31, 2026

Comeback from long-course ADT with relugolix (rel) and darolutamide (daro) in hormone-sensitive prostate cancer (PC) (CLEARED).

Atish Choudhury,
MD, PhD

Poster Session
Genitourinary Cancer:
Prostate, Testicular, and Penile
9:00am-12:00pm CT

Quantitative results from PSMAtrack: A prospective study evaluating changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer (mHSPC).

Praful Ravi, MBBChir,
MRCP

Poster Session
Genitourinary Cancer:
Prostate, Testicular, and Penile
9:00am-12:00pm CT

cfDNA-based signatures of nucleosome organization to enable prostate cancer subtyping.

Weiwei Bian, PhD

Poster Session
Genitourinary Cancer:
Prostate, Testicular, and Penile
9:00am-12:00pm CT

Indefinite versus 2 years fixed duration of immune checkpoint inhibition in metastatic non-small cell lung cancer.

Biagio Ricciuti, MD,
PhD

Poster Session
Lung Cancer: Non-Small Cell Metastatic
9:00am-12:00pm CT

Impact of STK11/KEAP1/SMARCA4 co-mutations in RAS-activated KRAS wild-type metastatic NSCLC treated with immune checkpoint inhibitors.

Cassio Murilo Hidalgo
Filho, MD

Poster Session
Lung Cancer: Non-Small Cell Metastatic
9:00am-12:00pm CT

Clinico-genomic landscape and prognostic impact of APC/CTNNB1 oncogenic alterations in non-small cell lung cancer.

Leonardo Brunetti,
MD

Poster Session
Lung Cancer: Non-Small Cell Metastatic
9:00am-12:00pm CT

Using stage-matched genomic analysis to support molecular similarity of unknown-primary Merkel cell carcinoma and identify ARID1B as a prognostic marker.

Furkan Bahar, MD

Poster Session
Melanoma/Skin Cancers
9:00am-12:00pm CT

A feasibility study of tumor-infiltrating lymphocytes (TIL) in patients with cutaneous squamous cell carcinoma and Merkel cell carcinoma after anti-PD-1 therapy.

Karam Khaddour, MD,
MS

Poster Session
Melanoma/Skin Cancers
9:00am-12:00pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Sunday, May 31, 2026 (continued)

Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma using a whole-genome sequencing-based ctDNA assay.

Karam Khaddour, MD,
MS

Poster Session
Melanoma/Skin Cancers
9:00am-12:00pm CT

Circulating tumor DNA (ctDNA) as a biomarker for pathologic response and clinical outcomes in patients with cutaneous squamous cell carcinoma (CSCC) receiving neoadjuvant anti-PD-1 therapy.

Luke Vest, MD

Poster Session
Melanoma/Skin Cancers
9:00am-12:00pm CT

Real-world challenges in the adoption of emerging therapies for extensive-stage small cell lung cancer in community settings.

Jacob Sands, MD

Poster Session
Lung Cancer: Non-Small Cell Local-Regional;
Small Cell; Other Thoracic Cancers
9:00am-12:00pm CT

Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).

Joaquim Bellmunt,
MD

Poster Session
Genitourinary Cancer: Kidney and Bladder
9:00am-12:00pm CT

A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma.

Marc Machaalani, MD

Poster Session
Genitourinary Cancer: Kidney and Bladder
9:00am-12:00pm CT

LIF expression as a predictive biomarker in metastatic renal cell carcinoma.

Mustafa Saleh, MD

Poster Session
Genitourinary Cancer: Kidney and Bladder
9:00am-12:00pm CT

Loss of chromosome Y and tumor immune phenotypes in metastatic renal cell carcinoma.

Pablo Barrios, MD

Poster Session
Genitourinary Cancer: Kidney and Bladder
9:00am-12:00pm CT

Use of NECTIN4 expression inferred from circulating chromatin to predict response and survival to enfortumab vedotin (EV) in metastatic urothelial carcinoma.

Rashad Nawfal, MD

Poster Session
Genitourinary Cancer: Kidney and Bladder
9:00am-12:00pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION	RESEARCHER	SESSION/TIME
Responses to trastuzumab deruxtecan (T-DXd) in HER2 IHC spectrum 2+ versus 3+ urothelial carcinoma across lines of therapy.	Sara El Sarout, MD	Poster Session Genitourinary Cancer: Kidney and Bladder <i>9:00am-12:00pm CT</i>
PEAK-1: A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell renal cell carcinoma.	Toni Choueiri, MD, FASCO	Poster Session Genitourinary Cancer: Kidney and Bladder <i>9:00am-12:00pm CT</i>
Correlation between CARINH expression and clinical outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).	Wassim Daoud Khatoun, MD	Poster Session Genitourinary Cancer: Kidney and Bladder <i>9:00am-12:00pm CT</i>

Monday, June 1, 2026

Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).	Caron Jacobson, MD, MMSc	Poster Session Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia <i>9:00am-12:00pm CT</i>
A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.	Matthew Davids, MD, MMSc	Poster Session Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia <i>9:00am-12:00pm CT</i>
Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome–negative acute lymphoblastic leukemia.	Daniel DeAngelo, MD, PhD	Poster Session Hematologic Malignancies: Leukemia, Myelodysplastic Syndromes, and Allograft Transplant <i>9:00am-12:00pm CT</i>
ASCERTAIN: Real-world asciminib (ASC) effectiveness in patients (pts) with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).	Marlise Luskin, MD	Poster Session Hematologic Malignancies: Leukemia, Myelodysplastic Syndromes, and Allograft Transplant <i>9:00am-12:00pm CT</i>

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Monday, June 1, 2026 (continued)

Azenosertib plus paclitaxel for platinum-resistant ovarian cancer: Results from a phase 1b study.

Joyce Liu, MD, MPH

Poster Session
Gynecologic Cancer
9:00am-12:00pm CT

Patient-perceived caregiver burden after intense oncology treatment.

Virgil Guo, BA

Poster Session
Quality Care/Health Services Research
9:00am-12:00pm CT

Actionable germline findings in endometrial cancer from a large multigene panel tested cohort.

Adela Rodriguez Hernandez, MD

Poster Session
Prevention, Risk Reduction, and Genetics
1:30pm-4:30pm CT

Leisure-time physical activity among US cancer survivors, 2020-2024.

Anna Tanasijevic, MPH

Poster Session
Prevention, Risk Reduction, and Genetics
1:30pm-4:30pm CT

Incorporating CA19-9 testing in a prospective study of pancreatic cancer surveillance (PCS) among high-risk individuals (HRIs).

Asaf Maoz, MD

Poster Session
Prevention, Risk Reduction, and Genetics
1:30pm-4:30pm CT

Association of thymic epithelial tumors (TETs) with Lynch syndrome (LS) per germline genetic testing and molecular tumor analysis.

Megan Dwyer, MS

Poster Session
Prevention, Risk Reduction, and Genetics
1:30pm-4:30pm CT

Investigating the molecular characteristics underlying desmoid tumor clinical trajectory.

Candace Haddox, MD

Poster Session
Sarcoma
1:30pm-4:30pm CT

SARC046: A phase II trial of nab-sirolimus in patients with progressing or symptomatic epithelioid hemangioendothelioma.

Michael Wagner, MD

Poster Session
Sarcoma
1:30pm-4:30pm CT

StrateGIST 3: A randomized, phase 3 study of velutinib (IDRX-42) versus sunitinib in patients with advanced gastrointestinal stromal tumors after imatinib therapy.

Suzanne George, MD

Poster Session
Sarcoma
1:30pm-4:30pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Monday, June 1, 2026 (continued)

Outcomes after recurrence on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with high-risk early-stage triple-negative breast cancer (eTNBC).

Chiara Corti, MD

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Gut microbiome characteristics in patients with hormone receptor-positive (HR+) HER2- breast cancer treated with adjuvant abemaciclib: Biomarker analysis of the TRADE trial.

Ilana Schlam, MD,
MPH

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.

Jose Leone, MD

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Breast cancer-specific mortality in invasive lobular versus ductal carcinoma over 30 years.

Jose Leone, MD

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Long-term safety outcomes of pregnancy among young breast cancer survivors: Results from a prospective, multicenter cohort study.

Kimia Sorouri, MD,
MPH

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

EA1181: Accuracy of pre-surgery MRI to predict pathologic complete response after taxane, trastuzumab, and pertuzumab (THP) in HER2-positive breast cancer.

Nadine Tung, MD,
FASCO

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Prognostic performance of a multimodal artificial intelligence histopathology-based tool versus the 21-gene recurrence score in early-stage breast cancer.

Nancy Lin, MD

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Adjuvant antibody-drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations.

Paolo Tarantino, MD,
PhD

Poster Session
Breast Cancer: Local/Regional/Adjuvant
1:30pm-4:30pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Monday, June 1, 2026 (continued)

Liquid-based methylation profiling of molecular breast cancer subtypes (MBS) in hormone receptor positive (HR+) metastatic breast cancer (MBC) treated with CDK4/6 inhibitor (CDK4/6i).

Daniel Abravanel, MD,
PhD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Organ- and histology-specific molecular and immune landscape of metastatic breast cancer.

Guilherme Nader
Marta, MD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)-positive breast cancer (TBCRC 070).

Kristina Fanucci, MD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Safety and efficacy of ZN-A-1041, a highly blood-brain barrier (BBB)-permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase I expansion results from the ZN-A-1041-101-US trial.

Nancy Lin, MD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Overall survival by genomic profile in HER2-positive (HER2+) metastatic breast cancer (mBC): A large US clinico-genomic database study.

Paolo Tarantino, MD,
PhD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2-advanced breast cancer.

Sara Tolaney, MD,
MPH, FASCO

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Development and evaluation of a novel digital pathology image analysis pipeline for prediction of clinical outcomes with the TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in triple-negative breast cancer (TNBC).

Sara Tolaney, MD,
MPH, FASCO

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Poster Presentations at 2026 ASCO Annual Meeting



Note: all times listed are Central Time

PRESENTATION

RESEARCHER

SESSION/TIME

Monday, June 1, 2026 (*continued*)

A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.

Stefania Morganti,
MD

Poster Session
Breast Cancer: Metastatic
1:30pm-4:30pm CT

Characterization of contemporary practice patterns in the management of IDH-mutant glioma: A multidisciplinary multi-institutional survey.

Luis Gonzalez Castro,
MD, PhD

Poster Session
Central Nervous System Tumors
1:30pm-4:30pm CT

Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastoma.

Patrick Wen, MD

Poster Session
Central Nervous System Tumors
1:30pm-4:30pm CT

Alliance A072301: A phase III trial of radiotherapy followed by adjuvant temozolomide in combination with vorasidenib vs placebo in IDH-mutated newly diagnosed grade 3 astrocytoma (VORTEX).

Ugonma Chukwueke,
MD, MPH

Poster Session
Central Nervous System Tumors
1:30pm-4:30pm CT

Clinical impact of panel-based next-generation sequencing in a real-world cohort of neuroblastoma patients.

Samantha Martin, MD

Poster Session
Pediatric Oncology
1:30pm-4:30pm CT

Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.

Samantha Martin, MD

Poster Session
Pediatric Oncology
1:30pm-4:30pm CT

Results of a phase II trial of nivolumab and ipilimumab in children and young adults with relapsed or refractory INI1-deficient cancers.

Suzanne Forrest, MD

Poster Session
Pediatric Oncology
1:30pm-4:30pm CT